Negus S S, Gatch M B, Mello N K, Zhang X, Rice K
Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA.
J Pharmacol Exp Ther. 1998 Jul;286(1):362-75.
The behavioral effects of the nonpeptidic delta opioid agonist SNC80 and a series of related piperazinyl benzamides derived from the parent compound BW373U86 were evaluated in rhesus monkeys. SNC80 (0.1-10 mg/kg) decreased response rates maintained by food-reinforcement in a dose- and time-dependent manner, with maximal effects occurring within 10 min of intramuscular injection. The potency of SNC80 and five other piperazinyl benzamides in this assay of schedule-controlled responding correlated with their affinity at cloned human delta opioid receptors but not with their affinity for cloned human mu receptors. Moreover, the effects of SNC80 were selectively antagonized by the delta-selective antagonist naltrindole (1.0 mg/kg), but not by the mu selective antagonist quadazocine (0.1 mg/kg) or the kappa-selective antagonist norbinaltorphimine (3.2 mg/kg). These findings indicate that SNC80 functions as a systemically active, delta-selective agonist with a rapid onset of action in rhesus monkeys. The antinociceptive effects of SNC80 were examined in a warm-water tail-withdrawal assay of thermal nociception. SNC80 (0.1-10 mg/kg) produced weak but replicable antinociceptive effects that were antagonized by naltrindole (1.0 mg/kg). SNC80 antinociception was also dose-dependently antagonized by BW373U86 (0.56-1.0 mg/kg), which was inactive in this procedure. These findings suggest that SNC80 may have higher efficacy than BW373U86 at delta opioid receptors. Moreover, SNC80 at doses up to 32 mg/kg did not produce convulsions, which suggests that SNC80 may also be safer than BW373U86. The effects of SNC80 were also examined in monkeys trained to discriminate cocaine (0.4 mg/kg i.m.) or self-administer cocaine (0.032 mg/kg/injection,i.v.). In drug discrimination studies, SNC80 (0.1-10 mg/kg) produced a dose-dependent and naltrindole-reversible increase in cocaine-appropriate responding, and complete substitution for cocaine was observed in five of seven monkeys tested. However, SNC80 (1.0-100 micrograms/kg/injection) did not maintain responding in monkeys trained to self-administer cocaine. Thus, despite its ability to produce cocaine-like discriminative stimulus effects, SNC80 may have relatively low abuse potential.
在恒河猴中评估了非肽类δ阿片受体激动剂SNC80以及一系列源自母体化合物BW373U86的相关哌嗪基苯甲酰胺的行为效应。SNC80(0.1 - 10mg/kg)以剂量和时间依赖性方式降低了由食物强化维持的反应率,肌肉注射后10分钟内出现最大效应。在这种程序控制反应试验中,SNC80和其他五种哌嗪基苯甲酰胺的效力与其对克隆的人δ阿片受体的亲和力相关,但与其对克隆的人μ受体的亲和力无关。此外,SNC80的效应被δ选择性拮抗剂纳曲吲哚(1.0mg/kg)选择性拮抗,但未被μ选择性拮抗剂夸达佐辛(0.1mg/kg)或κ选择性拮抗剂诺宾阿片苯吗喃(3.2mg/kg)拮抗。这些发现表明,SNC80在恒河猴中作为一种全身活性的δ选择性激动剂,起效迅速。在热痛觉的温水甩尾试验中检查了SNC80的抗伤害感受作用。SNC80(0.1 - 10mg/kg)产生了微弱但可重复的抗伤害感受作用,该作用被纳曲吲哚(1.0mg/kg)拮抗。SNC80的抗伤害感受作用也被BW373U86(0.56 - 1.0mg/kg)剂量依赖性拮抗,而BW373U86在此程序中无活性。这些发现表明,SNC80在δ阿片受体处可能比BW373U86具有更高的效力。此外,高达32mg/kg的SNC80剂量未产生惊厥,这表明SNC80可能也比BW373U86更安全。还在经过训练以辨别可卡因(0.4mg/kg,肌肉注射)或自我给药可卡因(0.032mg/kg/注射,静脉注射)的猴子中检查了SNC80的作用。在药物辨别研究中,SNC80(0.1 - 10mg/kg)使可卡因适当反应产生剂量依赖性且可被纳曲吲哚逆转的增加,并且在测试的七只猴子中有五只观察到完全替代可卡因。然而,SNC80(1.0 - 100μg/kg/注射)在经过训练以自我给药可卡因的猴子中未维持反应。因此,尽管SNC80有能力产生可卡因样的辨别性刺激效应,但其滥用潜力可能相对较低。